ORIGINAL ARTICLE

A single Epley manoeuvre can improve self-perceptions of disability (quality of life) in patients with pc-BPPV: A randomised controlled trial in primary care

Ricard Carrillo Muñoz\textsuperscript{a}, José Luis Ballve Moreno\textsuperscript{b,c,*}, Iván Villar Balboa\textsuperscript{a}, Yolanda Rando Matos\textsuperscript{b}, Oriol Cunillera Puertolas\textsuperscript{d}, Jesús Almeda Ortega\textsuperscript{d}, Vertigo Study Group in Florida Primary Care

\textsuperscript{a} Equip d’Atenció Primària Florida Nord, Institut Català de la Salut, L’Hospitalet de Llobregat, Barcelona, Spain \\
\textsuperscript{b} Equip d’Atenció Primària Florida Sud, Institut Català de la Salut, L’Hospitalet de Llobregat, Barcelona, Spain \\
\textsuperscript{c} Universitat de Barcelona, Barcelona, Spain \\
\textsuperscript{d} Unitat de Suport a la Recerca Metropolitana Sud, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Cornella, Barcelona, Spain

Received 4 February 2021; accepted 11 March 2021

KEYWORDS
Benign paroxysmal positional vertigo; Epley manoeuvre; Primary Care; Self-perceived disability

Abstract  

Posterior canal benign paroxysmal positional vertigo (pc-BPPV) causes physical, functional, and emotional impairment. The treatment is the Epley manoeuvre (EM).

Objective: The purpose of the study was to compare the impact of the EM and a sham manoeuvre in primary care on self-perceived disability.

Design: Randomised, double-blind, sham-controlled clinical trial conducted in primary care with a follow-up of 1 year.

Participants: Patients aged \( \geq \)18 years old diagnosed with pc-BPPV according to the Dix–Hallpike test (DHT) were randomised to:

Interventions: Intervention (EM) group or a control (sham manoeuvre) group.

Main measurements: The main study covariates were age, sex, history of depression and anxiety, presence of nystagmus in the DHT, patient-perceived disability assessed with the Dizziness Handicap Inventory – screening version (DHI-S). Data were analyzed using bivariate and multivariate mixed Tobit analyses.

Results: Overall, 134 patients were studied: 66 in the intervention group and 68 in the control group. Median age was 52 years (interquartile range [IQR], 38.25–68.00 years. standard deviation, 16.98) and 76.12% of the patients were women. The DHT triggered nystagmus in 40.30% of patients. The median total DHI-S score for the overall sample at baseline was 16 [IQR, 8.00–22.00]; 16 [IQR, 10.5–24.0] vs 10 [6.0–14.0] for women vs men (\( P < .001 \)). Patients treated with the EM experienced a mean reduction of 2.03 points in DHI-S score over the follow-up period compared with patients in the sham group.

1) Trial registration: ClinicalTrials.gov Identifier: NCT01969513. Retrospectively registered. First Posted: October 25, 2013. https://clinicaltrials.gov/ct2/show/NCT01969513.
2) Corresponding author.
E-mail address: ballvejl@gmail.com (J.L. Ballve Moreno).

https://doi.org/10.1016/j.aprim.2021.102077
0212-6567/© 2021 The Authors. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Impacto de la maniobra de Epley en la discapacidad autopercibida en pacientes con vértigo posicional paroxístico benigno: un ensayo controlado aleatorio en atención primaria

Resumen El vértigo posicional paroxístico benigno del canal posterior (pc-BPPV) causa deterioro físico, funcional y emocional. El tratamiento es la maniobra de Epley (ME).

Objetivo: El propósito del estudio fue comparar el impacto de la ME y una maniobra simulada en Atención Primaria sobre la discapacidad autopercibida.

Diseño: Ensayo clínico aleatorizado, doble ciego y controlado realizado en Atención Primaria con un seguimiento de un año.

Participantes: Los pacientes ≥18 años diagnosticados de pc-BPPV según la prueba de Dix-Hallpike (DHT) fueron aleatorizados para:

Intervenciones: Grupo de intervención (EM) o un grupo de control (maniobra simulada).

Variables principales: Las principales variables del estudio fueron la edad, el sexo, los antecedentes de depresión y ansiedad, la presencia de nistagmo en la DHT, la discapacidad percibida por el paciente, evaluada con la versión de cribado del Inventario de discapacidad del vértigo (DHI-S). Los datos se analizaron mediante análisis Tobit mixtos bivariados y multivariados.

Resultados: Se estudió a 134 pacientes: 66 en el grupo de intervención y 68 en el grupo de control. La mediana de edad fue de 52 años (rango intercuartílico [IQR], 38,25-68,00 años; desviación estándar 16,98) y el 76,12% de los pacientes eran mujeres. La DHT desencadenó nistagmo en el 40,30% de los pacientes. La media del DHI-S para la muestra general al inicio del estudio fue de 16 (IQR 8,00-22,00); 16 (RIQ, 10,5-24,0) frente a 10 (6,0-14,0) para mujeres frente a hombres (p < 0,001). Los pacientes tratados con ME experimentaron una reducción media de 2,03 puntos en la puntuación DHI-S durante el periodo de seguimiento en comparación con los pacientes del grupo simulado.

Conclusiones: El Pc-BPPV afecta a la calidad de vida de los pacientes de Atención Primaria. Una sola ME puede mejorar la autoperccepción de la discapacidad en alrededor de 2 puntos en la escala DHI-S.

© 2021 Los Autores. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Background

Benign paroxysmal positional vertigo (BPPV), the most frequent cause of vertigo, has an annual incidence ranging from 10.7 to 140 cases per 100,000 inhabitants and a lifetime prevalence of 2.4%. According to one systematic review, between 4.3% and 39.5% of patients seen in primary care for dizziness had BPPV. Posterior canal BPPV (pc-BPPV) is the most common variant and accounts for 60–90% of all cases.

PC-BPPV can be diagnosed with relative ease in primary care, as a targeted history, a basic physical examination, and performance of the Dix–Hallpike test (DHT) are sufficient to establish a diagnosis. The DHT is considered to be positive when it causes both vertigo and nystagmus. This form of BPPV is known as objective BPPV (O-BPPV). According to some authors, however, the DHT may also be considered positive if the patient experiences symptoms without nystagmus. This form of BPPV is known as subjective BPPV (S-BPPV) and it accounts for around 11.5–48% of all cases. Many patients with BPPV experience impaired physical and functional performance and the condition can also have an effect on family and social life. Vertigo increases the risk of falls, particularly among elderly patients, and also causes psychological symptoms that can lead patients to avoid certain everyday situations.

Perceived disability among patients with BPPV is usually assessed using standardised questionnaires, the most common being the Dizziness Handicap Inventory (DHI). for which several abbreviated versions have been created. One recent study comparing the original 25-item DHI with shorter versions reported that the Dizziness Handicap Inventory – screening version (DHI-S) was the best option as it shows strong correlation with the original DHI (r = 0.86) and has acceptable internal consistency (test–retest r = 0.95). The DHI-S was designed by Jacobson et al. and consists of 10 questions with the same “yes”, “sometimes” and
"no" answer options as the original questionnaire. It is a self-administered questionnaire that can be completed in 4–5 min, making it suitable for use in centres that have to deal with large numbers of patients such as primary care practices. It has been validated for use in Spain.16

The treatment of choice for BPPV is the Epley manoeuvre (EM), whose effectiveness has been demonstrated in numerous studies and systematic reviews.1,17,19 The EM is a canalicith repositioning manoeuvre that has been associated with improved self-perceptions of disability among patients with BPPV.16,20 It has also proven effective in elderly patients21 and in the long term, even after a single treatment.21

Although performance of the EM is feasible in primary care,23 most of the studies that have evaluated its impact on perceived disability among patients with pc-BPPV have been performed in specialised clinics. Studies thus are needed to evaluate its impact in patients diagnosed and treated in primary care.1

The aim of the study was to compare the effect of the EM and a sham manoeuvre on self-perceived disability assessed using the DHI-S at 1 week, 1 month, and 1 year in primary care patients with pc-BPPV.

Methods

Trial design

Randomised, double-blind, sham-controlled clinical trial with an allocation ratio of 1:1 conducted in two primary care practices.

Participants

Patients were recruited between November 2012 and January 2015, and three follow-up visits, held a week, a month, and a year after the intervention, were performed by six general practitioners (GPs) blinded to treatment allocation working at two primary care practices, which employ 26 GPs and offer care for 38 305 people in L’Hospitalet de Llobregat (Barcelona, Spain).

Eligible participants included all adults (≥18 years) with symptoms of vertigo seen at the primary care practices, and patients clinically suspected to have pc-BPPV were systematically recruited by the GPs involved in the study. Patients who agreed to participate were referred for baseline evaluation by one of six GPs on the research team. Those who provided written informed consent and had a positive DHT, with or without nystagmus (O-BPPV or S-BPPV, respectively), were included. Patients with purely vertical nystagmus, nystagmus lasting >1min, or vertical or alternating nystagmus were excluded and referred to an ear, nose, and throat (ENT) specialist. The full list of exclusion criteria is available in the study protocol.24

Changes to trial design

Although vestibular migraine was not an exclusion criterion for the trial,23 emerging evidence on the high prevalence of this condition25 and its overlapping symptoms with pc-BPPV suggested that patients with vestibular migraine might have been recruited for the trial. It was therefore decided to re-assess all patients after completion of the follow-up phase and to remove those who met the 2013 criteria for probable vestibular migraine.23 Results following the original trial design, including patients with probable vestibular migraine, are presented as supplementary material.

Interventions and comparisons

At the baseline visit, the patients underwent a full physical examination and a complete medical history, including review of electronic medical records.

Patients in the intervention group were treated with a single EM. They were prescribed betahistine 8 mg/8h and instructed to use the medication as required (maximum 3 times a day) until their symptoms improved.

Patients in the control group were prescribed betahistine as the same dosage. Instead of the EM, however, they received a sham manoeuvre consisting of laying the patient with his/her head turned towards the affected side for 5 min.27

The GPs who administered the EM took part in a 2-h practical training session on diagnosing vertigo and applying the manoeuvre under the supervision of an ENT specialist to ensure consistent execution across patients. Two videos showing an investigator administering the DHT (https://www.youtube.com/watch?v=tJEFl5RFZEM) and the EM (https://www.youtube.com/watch?v=yAFx4-TFGE) were also recorded.

Variables

The 10 items on the DHI-S are scored with 0 for "no", 2 for "sometime", and 4 for "yes". The total possible score therefore ranges from 0 (no self-perceived disability) to 40 (worst possible self-perceived disability).

The independent variables were age, sex, DHT result (O-BPPV or S-BPPV), history of anxiety and/or depression (Yes/No) and treatment with benzodiazepines, antidepressants, and/or vertigo drugs (Yes/No) at the time of the baseline visit.

Sample size

The sample size was calculated for outcomes not analysed in this study. Based on a sample size of 65 and 61 patients in the study arms at week 1, the study had a power of 80% to detect a statistically significant difference (alpha = 0.05) of 5.16 in DHI-S scores between groups (assuming a standard deviation of 10 in a Wilcoxon test [power estimated by bootstrap]).

Randomisation and allocation

Patients were assigned to the intervention and control groups using a unique list of randomisation sequences prepared in advance by the study statistician. The randomisation sequences were generated in ‘R: A language and
environment for statistical computing\(^1\), version 2.14.2 (R Foundation for Statistical Computing, Vienna, Austria).

**Statistical analysis**

Data were analysed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines,\(^2\) and comparisons between groups were based on the intention-to-treat principle.

Continuous variables (e.g., DHI-S scores) were expressed as median and interquartile range (IQR), while categorical variables (e.g., anxiety) were expressed as absolute and relative frequencies. For the between-group comparisons at each time point, the distribution of DHI-S scores was compared using the Chi-square test, while DHI-S scores were compared using the Wilcoxon test. These bivariate analyses were performed for the overall samples and stratified by sex and presence or absence of nystagmus at baseline.

A longitudinal multivariate regression model was built using DHI-S scores. Given the considerable proportion of 0 scores, a full mixed-effects multivariate Tobit regression model was adjusted to explain DHI-S scores by intervention, baseline DHI-S score, sex, baseline diagnosis (O-BPPV vs S-BPPV), and three-way interactions between all these variables and the treatment group, with adjustment for correlated intraindividual observations. Stepwise backward variable selection using the Akaike information criterion (AIC) was applied to obtain the final model. This reduced Tobit model contained all relevant variables and interactions; results are presented as marginal effects (medians of individual effects\(^9,30\)) and statistical significance \((P\text{-value})\) of the associated coefficients.

**Results**

Of the 330 patients with suspected pc-BPPV analysed, 134 (40.6\%) were included in the trial: 66 were randomised to the intervention group and 68 to the sham group. The reasons for exclusion are summarised in the study flowchart (Fig. 1). The main reason for exclusion was a negative DHT at baseline \((n = 123)\). Nineteen patients were removed retrospectively because they had criteria compatible with vestibular migraine. Their results, however, can be consulted in the supplementary material. The respective number of patients lost to follow-up at the three time points (week, month, and year) was 7, 17, and 21. The baseline characteristics for the overall sample and the intervention and control groups are shown in Table 1. The median age was 52 years (IQR, 38.25–68.00, standard deviation, 16.98) and 76.12\% of the patients were women. The DHT triggered nystagmus in 40.30\% of patients (O-BPPV). The proportion of patients with anxiety and depression was 25.38\% and 23.08\%, respectively. In total, 17.91\% of patients were being treated with benzodiazepines, 20.15\% with antidepressants, and 58.21\% with vertigo drugs at the baseline visit. No significant differences were observed between the intervention and control group for any of the study variables.

The median DHI-S score at baseline was 16 (IQR, 8.00–22.00). A higher median score was observed in women compared with men \((16 \text{ [IQR, 10.5–24.0] vs 10 [IQR, 6.0–14.0]}\), \(P < 0.001\) [not shown in table]) and in patients without nystagmus at baseline (S-BPPV) than in those with nystagmus \((16 \text{ [IQR, 10.0–24.0] vs 12 [8.0–18.0] for patients with O-BPPV; } P = 0.033\) [not shown in table]) (Tables 2a, 2b, 2c and 2d).

Patient-perceived disability during the follow-up period (week, month, year) was not influenced by a history of anxiety or depression or treatment with anxiolytics. The final multivariate model (the model with the best performance according to the AIC) showed that variations in DHI-S scores were explained by treatment group, baseline DHI-S score, follow-up (time point), and interaction between DHI-S score and time (all other interactions and effects did not provide enough likelihood to the model). Baseline DHI-S score was positively associated with DHI-S score during follow-up, with an initial marginal effect of 0.37 at week 1. The respective effects at 1 month and 1 year were 0.3 and 0.32 (significant decrease). According to the selection process, the interaction treatment \(\times\) time did not provide the model with sufficient predictive accuracy for these coefficients to be retained. In the final model thus, the treatment effect did not vary significantly over time, showing a stable marginal effect of \(-2.03 \text{ (–4.59, –0.06) points}\) (Table 3). The expected DHI values estimated by the multivariate model in Table 3 are shown in Fig. 2 according to the different exposure characteristics.

**Discussion**

**Summary**

Patients’ perceptions of pc-BPPV-associated disability assessed by the DHI-S improved after treatment with a single EM performed by GPs, with a significant difference in DHI-S scores of \(-2.03\) points compared with the sham group over the follow-up period; no significant variations were observed during this period.

Although the difference of \(-2.03\) points was significant, it may not have been clinically relevant, as the minimal detectable difference for the long version of the DHI is 17.68 points in the 0–100 theoretical range.\(^11\) Our results should, therefore, be interpreted with caution and it is important to consider the theoretical score ranges of the different versions of the DHI. We might also have observed greater differences if we had treated certain patients with more than one EM (the recommended number is up to four).\(^32\)

The median age of the patients in our series is similar to that observed in other studies at specialised clinics\(^6,31\) and primary care practices.\(^23\)

Also supporting previous findings,\(^2,20,33,34\) women outnumbered men in our study, which is consistent with the higher prevalence of pc-BPPV in women.\(^35–38\) No significant differences between men and women were found in terms of response to the EM during follow-up, even though baseline DHI-S scores were higher among women. Sex was not a significant factor in the multivariate model. Pereira et al.\(^20\) also reported similar responses to the EM in men and women.

Baseline patient perceptions of disability in our series (median DHI-S score, 16) were similar to those reported by Ardıç \textit{et al.}\(^14\) (mean, 16.4 ± 0.71), but better than those reported by patients treated at a specialised clinic (mean ± SD, 19.79 ± 10.14)\(^16\) and patients aged over 60
One possible explanation for the better scores in our series is that the patients were diagnosed and treated in primary care, avoiding the delays associated with referral to a specialist. Their younger age may also have played a part.

A high proportion of patients in our series had anxiety or depression. It is not uncommon for patients with BPPV to experience psychiatric-psychosomatic disorders such as depression or anxiety. Anxiety disorders, in fact, have been found to be 2.17 times (95% CI, 1.63–2.90, P < 0.001) more common in patients with BPPV than in controls following adjustment for age, sex, and comorbidities.

The main strength of our study is that it was conducted under typical conditions encountered in primary care practices, which is where most patients with BPPV are seen. We acknowledge some limitations of this study. The higher proportion of patients with S-BPPV detected in our series compared with earlier series indicates that we may have underestimated the prevalence of O-BPPV. Patients seen in primary care often have early-stage
| Table 1 | Characteristics of the study participants overall and by intervention. |
|---------|-------------------------------------------------------------|
|         | Overall | Sham manoeuvre (n = 68) | Epley manoeuvre (n = 66) | P value |
| Female, n (%) | 134 | 102 (76.12) | 50 (73.53) | 52 (78.79) | 0.546 |
| Age, median, (IQR) | 134 | 52.00 (38.25, 68.00) | 54.00 (40.75–72.00) | 50.50 (35.25–64.00) | 0.060 |
| Positive DHT with nystagmus, n (%) | 134 | 54 (40.30) | 25 (36.76) | 29 (43.94) | 0.482 |
| Anxiety, n (%) | 130 | 33 (25.38) | 15 (22.73) | 18 (28.12) | 0.548 |
| Depression, n (%) | 130 | 30 (23.08) | 15 (22.73) | 15 (23.44) | 1.000 |
| Benzodiazepines, n (%) | 134 | 24 (17.91) | 11 (16.18) | 13 (19.70) | 0.656 |
| Antidepressants, n (%) | 134 | 27 (20.15) | 13 (19.12) | 14 (21.21) | 0.831 |
| Medication for vertigo, n (%) | 134 | 78 (58.21) | 37 (54.41) | 41 (62.12) | 0.386 |

DHT: Dix–Hallpike test; IQR: interquartile range.

| Table 2a | Baseline evaluation. |
|---------|---------------------|
| N | Missing value | DHI-S Whole group | DHI-S Sham manoeuvre (n = 68) | DHI-S Epley manoeuvre (n = 66) | P value |
| 134 | 0 | 16.0 (8.0–22.0) | 14.0 (8.0–22.0) | 16.0 (10.0–22.0) | 0.537 |

By sex

| | Male | Female |
|---|---|---|
| | 32 | 102 |
| | 0 | 0 |
| | 10.0 (6.0–14.0) | 16.0 (10.5–24.0) |
| | 7.0 (6.0–13.5) | 16.0 (10.5–25.5) |
| | 11.0 (8.0–21.0) | 16.0 (11.5–24.0) |
| P value | 0.053 | 0.596 |

By nystagmus

| | S-BPPV | O-BPPV |
|---|---|---|
| | 80 | 54 |
| | 0 | 0 |
| | 16.0 (10.0–24.0) | 12.0 (8.0–18.0) |
| | 16.0 (10.0–24.0) | 12.0 (6.0–16.0) |
| | 18.0 (14.0–24.0) | 12.0 (8.0–18.0) |
| P value | 0.545 | 0.595 |

| Table 2b | Evaluation at 1 week. |
|---------|---------------------|
| N | Missing value | DHI-S Whole group | DHI-S Sham manoeuvre (n = 68) | DHI-S Epley manoeuvre (n = 66) | P value |
| 134 | 9 | 8.0 (2.0–14.0) | 8.0 (4.0–18.0) | 6.0 (0.0–14.0) | 0.175 |

By sex

| | Male | Female |
|---|---|---|
| | 32 | 102 |
| | 4 | 5 |
| | 2.0 (0.0–6.5) | 10.0 (4.0–18.0) |
| | 4.0 (2.0–8.0) | 10.0 (5.0–21.0) |
| | 2.0 (0.0–3.0) | 9.0 (0.5–14.0) |
| P value | 0.347 | 0.127 |

By nystagmus

| | S-BPPV | O-BPPV |
|---|---|---|
| | 80 | 54 |
| | 6 | 3 |
| | 8.0 (2.0–14.0) | 8.0 (2.0–15.0) |
| | 8.0 (3.5–15.0) | 9.0 (4.0–26.5) |
| | 7.0 (0.0–14.0) | 4.0 (1.0–13.0) |
| P value | 0.662 | 0.126 |

| Table 2c | Evaluation at 1 month. |
|---------|---------------------|
| N | Missing value | DHI-S Whole group | DHI-S Sham manoeuvre group (n = 68) | DHI-S Epley manoeuvre group (n = 66) | P value |
| 134 | 17 | 0.0 (0.0–10.0) | 2.0 (0.0–12.0) | 0.0 (0.0–6.0) | 0.140 |

By sex

| | Male | Female |
|---|---|---|
| | 32 | 102 |
| | 6 | 11 |
| | 0.0 (0.0–7.0) | 0.0 (0.0–12.0) |
| | 0.0 (0.0–6.0) | 4.0 (0.0–12.0) |
| | 0.0 (0.0–6.0) | 0.0 (0.0–6.0) |
| P value | 0.932 | 0.079 |

By nystagmus

| | S-BPPV | O-BPPV |
|---|---|---|
| | 80 | 54 |
| | 12 | 5 |
| | 0.0 (0.0–12.0) | 0.0 (0.0–10.0) |
| | 2.0 (0.0–12.0) | 2.0 (0.0–11.0) |
| | 0.0 (0.0–6.0) | 0.0 (0.0–7.0) |
| P value | 0.290 | 0.323 |
Table 2d  Evaluation at 1 year.

| N   | Missing value | DHI-S Whole group | DHI-S Sham manoeuvre group (n = 68) | DHI-S Epley manoeuvre group (n = 66) | P value |
|-----|---------------|-------------------|------------------------------------|--------------------------------------|---------|
| 134 | 22            | 0.0 (0.0–2.5)     | 0.0 (0.0–4.0)                      | 0.0 (0.0–2.0)                       | 0.506   |

By sex

|       | N  | Missing value | DHI-S Whole group | DHI-S Sham manoeuvre group (n = 68) | DHI-S Epley manoeuvre group (n = 66) | P value |
|-------|----|---------------|-------------------|------------------------------------|--------------------------------------|---------|
| Male  | 32 | 7             | 0.0 (0.0–4.0)     | 0.0 (0.0–3.5)                      | 0.0 (0.0–7.0)                       | 0.926   |
| Female| 102| 15            | 0.0 (0.0–2.0)     | 0.0 (0.0–4.0)                      | 0.0 (0.0–0.5)                       | 0.520   |

By nystagmus

|       | N  | Missing value | DHI-S Whole group | DHI-S Sham manoeuvre group (n = 68) | DHI-S Epley manoeuvre group (n = 66) | P value |
|-------|----|---------------|-------------------|------------------------------------|--------------------------------------|---------|
| S-BPPV| 80 | 13            | 0.0 (0.0–4.0)     | 0.0 (0.0–5.5)                      | 0.0 (0.0–2.0)                       | 0.472   |
| O-BPPV| 54 | 9             | 0.0 (0.0–0.0)     | 0.0 (0.0–0.0)                      | 0.0 (0.0–0.0)                       | 0.899   |

Table 3  Multivariate mixed-effects regression.

|                                           | Marginal effect (95% CI) | P value |
|-------------------------------------------|--------------------------|---------|
| (Intercept)                               | −1.05 (−3.72 to 1.76)    | 0.518   |
| Treatment group                           |                          |         |
| Sham group (reference)                    |                          |         |
| Epley manoeuvre group                     | −2.03 (−4.59 to −0.06)   | 0.045   |
| Baseline DHI-S score                      | 0.37 (0.27–0.53)         | <0.001  |
| Follow-up                                 |                          |         |
| Week (reference)                          |                          |         |
| Month                                     | −3.09 (−6.74 to 0.17)    | 0.130   |
| Year                                      | −1.26 (−5.62 to 2.61)    | 0.558   |
| Nystagmus at baseline                     | 1.78 (−0.37 to 4.18)     | 0.185   |
| Nystagmus at baseline follow-up           |                          |         |
| Baseline nystagmus after 1 month          | −1.68 (−5.12 to 1.25)    | 0.328   |
| Baseline nystagmus after 1 year           | −3.95 (−9.01 to −0.02)   | 0.039   |
| Baseline DHI-S score Follow-up            |                          |         |
| Baseline DHI-S after 1 month              | −0.03 (−0.20 to 0.14)    | 0.775   |
| Baseline DHI-S after 1 year               | −0.32 (−0.54 to −0.09)   | 0.003   |

Final model built following stepwise backward selection of variables using the Akaike Information Criterion from an initial model featuring treatment adjusted for follow-up, baseline DHI-S score, sex, nystagmus at baseline, and three-way interactions between these factors and treatment and follow-up. DHI-S: Dizziness Handicap Inventory – screening version.

Figure 2  Expected values from Table 3 estimated by the Tobit model with the best predictive accuracy according to treatment received (Epley manoeuvre [interv] vs sham manoeuvre [control]). Base DHI: baseline Dizziness Handicap Inventory – screening version score.
nystagmus, which is more difficult to diagnosis, particularly if special tools such as Frenzel goggles or video-nyctagmography are not used.\textsuperscript{41} The gold standard diagnostic work-up for pc-BPPV does not include these tools,\textsuperscript{42} but they can increase the number of O-BPPV cases diagnosed. Testing primary care patients with S-BPPV in addition to those with O-BBPV (greater diagnostic sensitivity at the expense of specificity) in primary care may improve early diagnosis and treatment rates, and such an approach has been suggested by other authors.\textsuperscript{43} The decision not to use Frenzel goggles or video-nyctagmography in our study was deliberate as we wished to reproduce the conditions faced by GPs in routine practice. Response to the EM in terms of perceived disability was not influenced by the presence or absence of nystagmus at baseline, supporting previous findings by Huebner et al.\textsuperscript{44} and Marques et al.\textsuperscript{45} Nonetheless, we cannot completely rule out the possibility that some of the patients in the S-BPPV group may have had vestibular neuritis or vestibular migraine.

Our findings for perceived disability contrast with previous findings for the same series of patients showing that the EM reversed positive DHTs and resulted in less severe vertigo in patients with O-BPPV but not S-BPPV.\textsuperscript{42}

Another possible limitation of the present paper is that initial sample size was calculated for other analyses, and this sample size was later reduced due to non-planned exclusion criteria. Although this could have led to lack of statistical power, our results found statistical significance for the main effect of the manoeuvre; further research is needed to discard any other possible effects, such as a time variation of the effect of the manoeuvre.

Implications for research and/or practice

The DHI-S is a simple tool that can be administered in a matter of minutes. It would therefore be interesting to determine cut-off points for different levels of perceived disability (none, mild, moderate, and severe).

It would also be interesting to calculate the minimal detectable change and minimal clinically important difference for the DHI-S in order to determine the relevance of changes over time.

BPPV can cause considerable disability. Early treatment of pc-BPPV using repositioning manoeuvres can result in significant improvements, highlighting the importance of prompt treatment in all patients, including those seen in primary care. It would be very interesting to determine whether performance of more than one EM would improve the outcomes observed in this study.

Conclusions

Pc-BPPV affects the quality of life of primary care patients. A single EM can improve self-perceptions of disability by around 2 points on the DHI-S scale. Nonetheless, although this difference is statistically significant, it may have little clinical relevance.

Keypoints

Benign paroxysmal positional vertigo, primary health care, Epley manoeuvre, health-related quality of life, randomised controlled trial.

- BPPV affects self-perceived disability.
- Performance of the EM is feasible in primary care.
- Patients’ perceptions of pc-BPPV-associated disability assessed by the DHI-S improved after treatment with a single EM performed by GPs.

Funding

This project received a research grant from the Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), awarded on the 2013 call under the Health Strategy Action 2013–2016, within the National Research Programme oriented to Societal Challenges, within the Technical, Scientific and Innovation Research National Plan 2013–2016, with reference PI13/01396, co-funded with European Union ERDF funds. It was also funded by the cycle XIV (2013) research grant from the Jordi Gol Institute for Research in Primary care (IDIAP Jordi Gol) (2014/005E).

Carlos III Institute of Health, Ministry of Economy and Competitiveness (Spain), provided the main amount of funding for the development and main management of the project. REAP funded the organisation of coordinating meetings and training.

IDIAP gave the grant to free up time to dedicate to the project as a predoctoral training of the author Jose Luis Balive.

IDIAP Jordi Gol also funded the translation of this article into English.

Authors’ contributions

RCM, JLBM, YRM and IVB: conception, design and drafting, data collection and analysis, writing and final approval of manuscript. OCP: statistical analysis, design and drafting, analysis and interpretation of data, writing and final approval of manuscript. JAO: conception, design and drafting, analysis and interpretation of data, writing and final approval of manuscript. JPP, OLAA: data collection and analysis, critical review and final approval of manuscript.

Conflict of interests

The authors declare that they have no competing interests.

Acknowledgements

The authors gratefully acknowledge the technical and scientific assistance provided by the Primary Healthcare Research Unit of Costa de Ponent Primary Healthcare University Research Institute IDIAP-Jordi Gol. We also thank Neus
Profitós and Celsa Fernández who were responsible for safeguarding the randomisation sequence list. Finally, we thank all the participants of the Grupo de Estudio del Vértigo en Atención Primaria Florida: José Luis Ballvé Moreno, Yolanda Rando Matos, Estrella Rodero Pérez, Xavier Monteverde Curtó, Carles Rubio Ripollès, Noemi Moreno Farrés, Jean Carlos Gómez Nova, Johan José Villarreal Miñano, Diana Lizzeth Pacheco Erazo, Raquel Adrover Martori, Anna Aguilar Margalejo, Olga Lucia Arias Agudelo, Silvia Cañadas Crespo, Laura Illamola Martín, Marta Sarró Maluquer, Lluís Solsona Díaz, Rosa Sorando Alastruey (Equip d’Atenció Primària Florida Nord, Institut Català de la Salut, Hospital de Llobregat, Barcelona, Spain).

Ricard Carrillo Muñoz, Iván Villar Balboa, Austria Matos Méndez, Marta Bardina Santos (Equip d’Atenció Primària Florida Sud, Institut Català de la Salut, Hospital de Llobregat, Barcelona, Spain).

Oriol Cuñillera Puértolas and Jesús Almeda Ortega (Unidad de Suport a la Recerca Costa de Ponent, Institut Universitari d’Investigació en Atenció Primària Jordi Gol Cornellà, Spain) Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain

Lead author: José Luis Ballvé Moreno.

Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.aprim.2021.102077.

References

1. Bhattacharyya N, Gubbel's SP, Schwartz SR, Edlow JA, El-Kashlan H, Fife T, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update) executive summary. Otolaryngol Head Neck Surg. 2017;156:403–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28248602

2. von Brevens M, Radtke A, Lezitis F, Feldmann M, Ziese T, Lempert O, et al. Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry. 2007;78:710–5. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2117684&tool=pmcentrez&rendertype=Abstract

3. Bösnerr S, Schwarm S, Grevennath P, Schmidt L, Hörner K, Beidatsch D, et al. Prevalence, aetiologies and prognosis of the symptom dizziness in primary care– a systematic review. BMC Fam Pract. 2018;19:33. http://dx.doi.org/10.1186/s12875-017-0695-0 [Published 20.02.18].

4. Kim JS, Oh SY, Lee SH, Kang JH, Kim DU, Jeong SH, et al. Randomized clinical trial for apogeotropic horizontal canal benign paroxysmal positional vertigo. Neurology. 2012;78:159–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22170885

5. Dix MR, Hallpike CS. The pathology symptomatology and diagnosis of certain common disorders of the vestibular system. Proc R Soc Med. 1952;45:341–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/13008328

6. Haynes DS, Resser JR, Labadie RF, Girasole CR, Kovach BT, Scheker LE, et al. Treatment of benign positional vertigo using the semont maneuver: efficacy in patients presenting without nystagmus. Laryngoscope. 2002;112:796–801.

7. Balatsouras DG, Korres SG. Subjective benign paroxysmal positional vertigo. Otolaryngol Neck Surg. 2012;146:98–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21998085

8. Konstein AM, Golding JF, Grearty MA, Handalá M, Nuti D, Shetty A, et al. The social impact of dizziness in London and Siena. J Neurol. 2010;257:183–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19701661

9. Carrillo R, Ballvé JL, Villar I, et al. Disability perceived by primary care patients with posterior canal benign paroxysmal positional vertigo. BMC Fam Pract. 2019;20:156, http://dx.doi.org/10.1186/s12875-019-1035-3.

10. Agrawal Y, Ward BK, Minor LB. Vestibular dysfunction: prevalence, impact and need for targeted treatment. J Vestib Res Equilib Orientat. 2013;23:113–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24177344

11. Scherer S, Lisboa HRK, Pasquelotti A. Tontura en idosos: diagnóstico otorrinolaringológico e interferência na qualidade de vida. Rev da Soc Bras Fonoaudiol. 2012;17:142–50. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid= S1516-80342012000200076lang=pt

12. Yardley L, Redfern MS. Psychological factors influencing recovery from balance disorders. J Anxiety Disord. 2001;15:107–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11388354

13. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg. 1990;116:424–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2317532

14. Ardiç FN, Tümkaya F, Akdağ B, Şenol H. The subscales and short forms of the dizziness handicap inventory: are they useful for comparison of the patient groups? Disabil Rehabil. 2017;39:2119–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27548005

15. Jacobson GP, Calder JH. A screening version of the Dizziness Handicap Inventory (DHI-S). Am J Otol. 1998;19:804–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9831158

16. López-Escámez JA, Gómez-Fihana M, Fernández A, Sánchez-Cañet I, Palma MJ, Rodriguez J. Evaluation of the treatment of benign paroxysmal positional vertigo with the DHI-S questionnaire. Acta Otorrinolaringol Esp. 2001;52:660–6.

17. Hilton MP, Pinder DK. The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo. In: Hilton MP, editor. The Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd.; 2014. p. 36–7, http://dx.doi.org/10.1002/14651858.CD003162.pub3

18. Teixeira LJ, Machado JNP. Maneuvers for the treatment of benign positional paroxysmal vertigo: a systematic review. Braz J Otorhinolaryngol. 2006;72:130–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16917565

19. Helminski JO, Zee DS, Janssen I, Hain TC. Effectiveness of particle repositioning maneuvers in the treatment of benign paroxysmal positional vertigo: a systematic review. Phys Ther. 2010;90:661–78.

20. Pereira AB, Santos JN, Volpe FM. Effect of Epley’s maneuver on the quality of life of paroxysmal positional benign vertigo patients. Braz J Otorhinolaryngol. 2010;76:704–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21180936

21. Gámiz MJ, López-Escámez JA. Health-related quality of life in patients over sixty years old with benign paroxysmal positional vertigo. Gerontology. 2004;50:82–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14963374

22. López-Escámez JA, Gámiz MJ, Fernandez-Perez A, Gomez-Fiñana M. Long-term outcome and health-related quality of life in benign paroxysmal positional vertigo. Eur Arch Otorhinolaryngol. 2005;262:507–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15942805
23. Munoz JE, Miklea JT, Howard M, SprinGate R, Kaczorowski J. Canalith repositioning maneuver for benign paroxysmal positional vertigo: randomized controlled trial in primary practice. Can Fam Physician. 2007;53:1049-53, 1048. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17872784?tool=pubmed&from=pubmed&dftlang=en&indexname=nchin&domain=abstract&searchid=1&search=can%20fam%20physician&current=1&isfmt=pubmed&sort=pubdate&report=abstract&docshrt=1&gcontext=freetext

24. Ballve Moreno JL, Carrillo Muñoz R, Villar Balboa I, Rando Matos Y, Arias Aguadlo OL, Vasudeva A, et al. Effectiveness of the Epley’s maneuver performed in primary care to treat posterior canal benign paroxysmal positional vertigo: study protocol for a randomized controlled trial. Trials. 2014;15:179. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3949221

25. Dieterich M, Obermann M, Celebisyö N. Vestibular migraine: the most frequent entity of episodic vertigo. J Neurol. 2016;263 Suppl.:S82–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27083888

26. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23771276

27. Froehling DA, Bowen JM, Mohr DN, Brey RH, Beatty CW, Wolfl C, et al. The canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo: a randomized controlled trial. Mayo Clin Proc. 2000;75, http://dx.doi.org/10.4065/75.7.6953

28. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMJ. 2010;340:c332.

29. Cunillera O. Tobit models. In: Michalos AC, editor. Encyclopedia of quality of life and well-being research. Netherlands: Springer; 2014. p. 6671–6.

30. Greene WH. Econometric analysis. 5th edition Upper Saddle River: Prentice Hall; 2003. p. 764.

31. Enloe LJ, Shields RK. Evaluation of health-related quality of life in individuals with vestibular disease using disease-specific and general outcome measures. Phys Ther. 1997;77:890–903.

32. Moreno NS, Do Rego André AP. Number of maneuvers need to get a negative Dix–Hallpike test. Braz J Otorhinolaryngol. 2009;75:650–3.

33. Petri M, Chiriłă M, Balboacă SD, Cosgarea M. Health-related quality of life and disability in patients with acute unilateral peripheral vestibular disorders. Braz J Otorhinolaryngol. 2016;83:611–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27599524

34. Obermann M, Bock E, Sabev N, Lehmann N, Weber R, Gerwig M, et al. Long-term outcome of vertigo and dizziness associated disorders following treatment in specialized tertiary care: the Dizziness and Vertigo Registry (DiVeR) Study. J Neurol. 2015;262:2083–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26092518

35. Da Silva CN, Ribeiro KMOBF, Freitas RVD, Ferreira LMDBM, Guerra RO. Vertiginous symptoms and objective measures of postural balance in elderly people with benign paroxysmal positional vertigo submitted to the Epley maneuver. Int Arch Otorhinolaryngol. 2016;20:61–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26722348

36. Neuhauser HK, Radtke A, von Brevn M, Lezious F, Feldmann M, Lempert T. Burden of dizziness and vertigo in the community. Arch Intern Med. 2008;168:2118–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18955641

37. de Ribeiro KMOBF, Ferreira LMDBM, Freitas RVD, da Silva CN, Deshpande N, Guerra RO. “Positive to negative” Dix–Hallpike test and benign paroxysmal positional vertigo recurrence in elderly undergoing canalith repositioning maneuver and vestibular rehabilitation. Int Arch Otorhinolaryngol. 2016;20:344–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27746838

38. Chen Z-J, Chang C-H, Hu L-Y, Tu M-S, Lu T, Chen P-M, et al. Increased risk of benign paroxysmal positional vertigo in patients with anxiety disorders: a nationwide population-based retrospective cohort study. BMC Psychiatry. 2016;16:238. Available from: http://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-016-0950-2

39. Ferrari S, Monzani D, Baraldi S, Simoni E, Prati G, Forghieri M, et al. Vertigo “in the pink”?: the impact of female gender on psychiatric-psychosomatic comorbidity in benign paroxysmal positional vertigo patients. Psychosomatics. 2014;55:280–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23756120

40. Huebner AC, Lytle SR, Doettl SM, Pylter PN, Thelin JT. Treatment of objective and subjective benign paroxysmal positional vertigo. J Am Acad Audiol. 2013;24:600–6. Available from: http://www.scopus.com/inward/record.url?scp=8484798328&partnerID=tZOtx3y1

41. Tirelli G, D’Orlando E, Giacomarra V, Russolo M. Benign positional vertigo without detectable nystagmus. Laryngoscope. 2001;111:1053–6. http://dx.doi.org/10.1097/00005537-200106000-00022.

42. Marques PS, Castillo R, Santos M, Perez-Fernandez N. Repositioning nystagmus: diagnostic usefulness? Acta Otolaryngol. 2014;134:491–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24702230

43. Ballvé JL, Carrillo-Muñoz R, Rando-Matos Y, Villar I, Cunillera O, Almeda J, et al. Effectiveness of the Epley manoeuvre in posterior canal benign paroxysmal positional vertigo: a randomised clinical trial in primary care. Br J Gen Pract. 2019;69:e52–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30510098